{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,25]],"date-time":"2026-01-25T05:34:41Z","timestamp":1769319281628,"version":"3.49.0"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T00:00:00Z","timestamp":1746748800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jni-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Neuroimmunology"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.jneuroim.2025.578635","type":"journal-article","created":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T11:23:22Z","timestamp":1746530602000},"page":"578635","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Anti-IL-6 receptor antibody suppresses onset of paralytic symptoms in AQP4 peptide-immunized mice without lowering bone strength or mineral density"],"prefix":"10.1016","volume":"405","author":[{"given":"Haruna","family":"Tomizawa-Shinohara","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshihiro","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shota","family":"Miyake","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshichika","family":"Katsura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keisuke","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenichi","family":"Serizawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jneuroim.2025.578635_bb0005","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.608149","article-title":"Early treatment initiation with Oral prednisolone for relapse prevention alleviates depression and fatigue in Aquaporin-4-positive Neuromyelitis optica Spectrum disorder","volume":"12","author":"Akaishi","year":"2021","journal-title":"Front. Neurol."},{"key":"10.1016\/j.jneuroim.2025.578635_bb0010","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1111\/cei.12733","article-title":"Prediction of disease severity in neuromyelitis optica by the levels of interleukin (IL)-6 produced during remission phase","volume":"183","author":"Barros","year":"2016","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.jneuroim.2025.578635_bb0015","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/s41574-020-0341-0","article-title":"Pathogenesis of glucocorticoid-induced osteoporosis and options for treatment","volume":"16","author":"Chotiyarnwong","year":"2020","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.jneuroim.2025.578635_bb0020","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/BF03350919","article-title":"Bone microarchitecture as an important determinant of bone strength","volume":"27","author":"Dalle Carbonare","year":"2004","journal-title":"J. Endocrinol. Investig."},{"key":"10.1016\/j.jneuroim.2025.578635_bb0025","doi-asserted-by":"crossref","first-page":"3551","DOI":"10.1002\/art.22175","article-title":"Impaired skeletal development in interleukin-6-transgenic mice: a model for the impact of chronic inflammation on the growing skeletal system","volume":"54","author":"De Benedetti","year":"2006","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jneuroim.2025.578635_bb0030","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1530\/eje.1.02147","article-title":"High-dose glucocorticoids increase serum levels of soluble IL-6 receptor alpha and its ratio to soluble gp130: an additional mechanism for early increased bone resorption","volume":"154","author":"Dovio","year":"2006","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.jneuroim.2025.578635_bb0035","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1002\/(SICI)1097-0185(199609)246:1<39::AID-AR5>3.0.CO;2-A","article-title":"Trabecular and endocortical bone surfaces in the rat: modeling or remodeling?","volume":"246","author":"Erben","year":"1996","journal-title":"Anat. Rec."},{"key":"10.1016\/j.jneuroim.2025.578635_bb0040","first-page":"7","article-title":"Interleukin-6 in neuromyelitis optica spectrum disorder pathophysiology","author":"Fujihara","year":"2020","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.jneuroim.2025.578635_bb0045","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s40263-023-00995-9","article-title":"Satralizumab: a review in Neuromyelitis Optica Spectrum disorder","volume":"37","author":"Fung","year":"2023","journal-title":"CNS Drugs"},{"key":"10.1016\/j.jneuroim.2025.578635_bb0050","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1007\/s00223-017-0335-7","article-title":"Glucocorticoids, inflammation and bone","volume":"102","author":"G\u00fcler-Y\u00fcksel","year":"2018","journal-title":"Calcif. Tissue Int."},{"key":"10.1016\/j.jneuroim.2025.578635_bb0055","doi-asserted-by":"crossref","first-page":"E2677","DOI":"10.1073\/pnas.1424774112","article-title":"Interleukin-6\/interleukin-21 signaling axis is critical in the pathogenesis of pulmonary arterial hypertension","volume":"112","author":"Hashimoto-Kataoka","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.jneuroim.2025.578635_bb0060","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1093\/rheumatology\/ken363","article-title":"IL-6 trans-signalling directly induces RANKL on fibroblast-like synovial cells and is involved in RANKL induction by TNF-alpha and IL-17","volume":"47","author":"Hashizume","year":"2008","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jneuroim.2025.578635_bb0065","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3109\/00207450903428970","article-title":"Enhanced IL-6 production in aquaporin-4 antibody positive neuromyelitis optica patients","volume":"120","author":"I\u00e7\u00f6z","year":"2010","journal-title":"Int. J. Neurosci."},{"key":"10.1016\/j.jneuroim.2025.578635_bb0070","series-title":"Endotext [Internet]","article-title":"An overview of glucocorticoid-induced osteoporosis","author":"Ilias","year":"2000"},{"key":"10.1016\/j.jneuroim.2025.578635_bb0075","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1136\/jnnp-2012-302310","article-title":"Current concept of neuromyelitis optica (NMO) and NMO spectrum disorders","volume":"84","author":"Jacob","year":"2013","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.jneuroim.2025.578635_bb0080","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1007\/s00774-013-0514-1","article-title":"IL-6 negatively regulates osteoblast differentiation through the SHP2\/MEK2 and SHP2\/Akt2 pathways in vitro","volume":"32","author":"Kaneshiro","year":"2014","journal-title":"J. Bone Miner. Metab."},{"key":"10.1016\/j.jneuroim.2025.578635_bb0085","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1007\/s13311-015-0400-8","article-title":"Present and future therapies in Neuromyelitis Optica Spectrum disorders","volume":"13","author":"Kleiter","year":"2016","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.jneuroim.2025.578635_bb0090","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.ejphar.2015.03.028","article-title":"Animal models for osteoporosis","volume":"759","author":"Komori","year":"2015","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.jneuroim.2025.578635_bb0095","article-title":"Osteoporosis in a woman with multiple sclerosis: a case report","volume":"16","author":"Kostoglou-Athanasiou","year":"2024","journal-title":"Cureus"},{"key":"10.1016\/j.jneuroim.2025.578635_bb0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102080","article-title":"Bone health in neuromyelitis optica: bone mineral density and fractures","volume":"42","author":"Kwon","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.jneuroim.2025.578635_bb0105","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1016\/S0140-6736(04)17551-X","article-title":"A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis","volume":"364","author":"Lennon","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.jneuroim.2025.578635_bb0110","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1084\/jem.20050304","article-title":"IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel","volume":"202","author":"Lennon","year":"2005","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.jneuroim.2025.578635_bb0115","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1136\/annrheumdis-2017-212880","article-title":"In vivo visualisation of different modes of action of biological DMARDs inhibiting osteoclastic bone resorption","volume":"77","author":"Matsuura","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jneuroim.2025.578635_bb0120","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2024.1356300","article-title":"IL-6 receptor antibody treatment improves muscle weakness in experimental autoimmune myasthenia gravis mouse model","volume":"15","author":"Miyake","year":"2024","journal-title":"Front. Neurol."},{"key":"10.1016\/j.jneuroim.2025.578635_bb0125","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/S0165-2478(02)00202-X","article-title":"Characterization of anti-mouse interleukin-6 receptor antibody","volume":"84","author":"Okazaki","year":"2002","journal-title":"Immunol. Lett."},{"key":"10.1016\/j.jneuroim.2025.578635_bb0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.steroids.2024.109440","article-title":"A comprehensive review on glucocorticoids induced osteoporosis: a medication caused disease","volume":"207","author":"Rahman","year":"2024","journal-title":"Steroids"},{"key":"10.1016\/j.jneuroim.2025.578635_bb0135","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1007\/s00223-021-00836-1","article-title":"Disuse osteoporosis: clinical and mechanistic insights","volume":"110","author":"Rolvien","year":"2022","journal-title":"Calcif. Tissue Int."},{"key":"10.1016\/j.jneuroim.2025.578635_bb0140","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1084\/jem.20061775","article-title":"Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction","volume":"203","author":"Sato","year":"2006","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.jneuroim.2025.578635_bb0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2023.578109","article-title":"Intradermal AQP4 peptide immunization induces clinical features of neuromyelitis optica spectrum disorder in mice","volume":"380","author":"Serizawa","year":"2023","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jneuroim.2025.578635_bb0150","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jot.2018.07.001","article-title":"Strain-specific differences in the development of bone loss and incidence of osteonecrosis following glucocorticoid treatment in two different mouse strains","volume":"16","author":"Shidara","year":"2019","journal-title":"J. Orthop. Translat."},{"key":"10.1016\/j.jneuroim.2025.578635_bb0155","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/cei.12685","article-title":"Blockade of interleukin-6 receptor enhances the anti-arthritic effect of glucocorticoids without decreasing bone mineral density in mice with collagen-induced arthritis","volume":"182","author":"Suzuki","year":"2015","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.jneuroim.2025.578635_bb0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.102750","article-title":"Optimal management of neuromyelitis optica spectrum disorder with aquaporin-4 antibody by oral prednisolone maintenance therapy","volume":"49","author":"Takai","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.jneuroim.2025.578635_bb0165","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1038\/nri2062","article-title":"Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems","volume":"7","author":"Takayanagi","year":"2007","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.jneuroim.2025.578635_bb0170","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1007\/s00415-009-5274-4","article-title":"Markedly increased CSF interleukin-6 levels in neuromyelitis optica, but not in multiple sclerosis","volume":"256","author":"Uzawa","year":"2009","journal-title":"J. Neurol."},{"key":"10.1016\/j.jneuroim.2025.578635_bb0175","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1159\/000339302","article-title":"Notable increased cerebrospinal fluid levels of soluble interleukin-6 receptors in neuromyelitis optica","volume":"19","author":"Wang","year":"2012","journal-title":"Neuroimmunomodulation"},{"key":"10.1016\/j.jneuroim.2025.578635_bb0180","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2025.578635_bb0185","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1080\/03009742.2017.1416667","article-title":"Anti-interleukin-6 receptor antibody prevents loss of bone structure and bone strength in collagen-induced arthritis mice","volume":"47","author":"Yoshida","year":"2018","journal-title":"Scand. J. Rheumatol."}],"container-title":["Journal of Neuroimmunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016557282500116X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016557282500116X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T10:11:34Z","timestamp":1762251094000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016557282500116X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":37,"alternative-id":["S016557282500116X"],"URL":"https:\/\/doi.org\/10.1016\/j.jneuroim.2025.578635","relation":{},"ISSN":["0165-5728"],"issn-type":[{"value":"0165-5728","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anti-IL-6 receptor antibody suppresses onset of paralytic symptoms in AQP4 peptide-immunized mice without lowering bone strength or mineral density","name":"articletitle","label":"Article Title"},{"value":"Journal of Neuroimmunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jneuroim.2025.578635","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"578635"}}